Evidence map›Paper›PMID 31692971›Full record

ArticleWorld journal of stem cells2019

Unmodified autologous stem cells at point of care for chronic myocardial infarction.

Alexander Haenel, Mohamad Ghosn, Tahereh Karimi, Jody Vykoukal, Dipan Shah, Miguel Valderrabano, Daryl G Schulz, Albert Raizner, Christoph Schmitz, Eckhard U Alt

Open access · hybridAbstract read
In one paragraph

Article in World journal of stem cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Stem Cell Therapy against Ischemic Heart Disease.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Alexander HaenelHeart and Vascular Institute, Department of Medicine, Tulane University Health Science Center, New Orleans, LA 70112, United States.
Mohamad GhosnHouston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, United States.
Tahereh KarimiHeart and Vascular Institute, Department of Medicine, Tulane University Health Science Center, New Orleans, LA 70112, United States.
Jody VykoukalDepartment of Translational Molecular Pathology, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, United States.
Dipan ShahHouston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, United States.
Miguel ValderrabanoHouston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, United States.
Daryl G SchulzThe Methodist Hospital Research Institute, Houston, TX 77030, United States.
Albert RaiznerHouston Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, United States.
Christoph SchmitzInstitute of Anatomy, Faculty of Medicine, LMU Munich, Munich D-80336, Germany.
Eckhard U AltHeart and Vascular Institute, Department of Medicine, Tulane University Health Science Center, New Orleans, LA 70112, United States.
Houston Methodist · USTulane University · USLudwig-Maximilians-Universität München · DEThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNumerous studies investigated cell-based therapies for myocardial infarction (MI). The conflicting results of these studies have established the need for developing innovative approaches for applying cell-based therapy for MI. Experimental studies on animal models demonstrated the potential of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) for treating acute MI. In contrast, studies on the treatment of chronic MI (CMI; > 4 wk post-MI) with UA-ADRCs have not been published so far. Among several methods for delivering cells to the myocardium, retrograde delivery into a temporarily blocked coronary vein has recently been demonstrated as an effective option.

aimTo test the hypothesis that in experimentally-induced chronic myocardial infarction (CMI; > 4 wk post-MI) in pigs, retrograde delivery of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) into a temporarily blocked coronary vein improves cardiac function and structure.

methodsThe left anterior descending (LAD) coronary artery of pigs was blocked for 180 min at time point T0. Then, either 18 × 10

resultsUnlike the delivery of saline, delivery of UA-ADRCs demonstrated statistically significant improvements in cardiac function and structure at T2 compared to T1 (all values given as mean ± SE): Increased mean LVEF (UA-ADRCs group: 34.3% ± 2.9% at T1

conclusionRetrograde cell delivery of UA-ADRCs in a porcine model for the study of CMI significantly improved myocardial function, increased myocardial mass and reduced the formation of scar tissue.

Indexed as

Adipose tissue-derived regenerative cellsChronic myocardial infarctionHeart failurePoint of care cell therapyStem cellsTranslational medicine

Identifiers

PMID31692971
PMCPMC6828597
OpenAlexW2980637655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.